Novogen Limited, is an Australia-based biotechnology company. The Company owns two drug technology platforms. The Company targets unmet clinical needs and has therapeutic potential across cancer, degenerative disorders, autoimmune disease and regenerative medicine. The Company aims to enable cytotoxic chemotherapy to eradicate most forms of cancer. The drug technologies include: Super-Benzopyrans and Anti-Tropomyosins. Super-Benzopyrans, possess the ability to kill cancer stem cells, prevent cancer recurrence, potential to become standard of care for first-line therapy across most forms of cancer, and manageable toxicity. Anti-Tropomyosins, drug targeting cancer cell’s micro-filaments, complement the action of used drugs in oncology, and potential to become standard of care in combination with taxanes and vinca alkaloids.